Bourantas KL - Search Results

1

Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases.

Panteli KE, Hatzimichael EC, Bouranta PK, Katsaraki A, Seferiadis K, Stebbing J, Bourantas KL. Panteli KE, et al. Among authors: bourantas kl. Br J Haematol. 2005 Sep;130(5):709-15. doi: 10.1111/j.1365-2141.2005.05674.x. Br J Haematol. 2005. PMID: 16115126 Free article.

2

Serum levels of IL-6 and its soluble receptor (sIL-6R) in Waldenström's macroglobulinemia.

Hatzimichael EC, Christou L, Bai M, Kolios G, Kefala L, Bourantas KL. Hatzimichael EC, et al. Among authors: bourantas kl. Eur J Haematol. 2001 Jan;66(1):1-6. doi: 10.1034/j.1600-0609.2001.00152.x. Eur J Haematol. 2001. PMID: 11168500

3

Serum levels, and bone marrow immunohistochemical expression of, vascular endothelial growth factor in patients with chronic myeloproliferative diseases.

Panteli K, Bai M, Hatzimichael E, Zagorianakou N, Agnantis NJ, Bourantas K. Panteli K, et al. Hematology. 2007 Dec;12(6):481-6. doi: 10.1080/10245330701554664. Hematology. 2007. PMID: 17852434 Free article.

4

Serum beta-2-microglobulin, TNF-alpha and interleukins in myeloproliferative disorders.

Bourantas KL, Hatzimichael EC, Makis AC, Chaidos A, Kapsali ED, Tsiara S, Mavridis A. Bourantas KL, et al. Eur J Haematol. 1999 Jul;63(1):19-25. doi: 10.1111/j.1600-0609.1999.tb01845.x. Eur J Haematol. 1999. PMID: 10414450

5

Alpha-2-macroglobulin and interleukin-6 levels in steady-state sickle cell disease patients.

Makis AC, Hatzimichael EC, Mavridis A, Bourantas KL. Makis AC, et al. Among authors: bourantas kl. Acta Haematol. 2000;104(4):164-8. doi: 10.1159/000046509. Acta Haematol. 2000. PMID: 11279305

6

Clinical correlation of bone marrow microvessel density in essential thrombocythemia.

Panteli K, Zagorianakou N, Agnantis NJ, Bourantas KL, Bai M. Panteli K, et al. Among authors: bourantas kl. Acta Haematol. 2005;114(2):99-103. doi: 10.1159/000086583. Acta Haematol. 2005. PMID: 16103633

7

Serum ferritin, transferrin and soluble transferrin receptor levels in multiple sclerosis patients.

Sfagos C, Makis AC, Chaidos A, Hatzimichael EC, Dalamaga A, Kosma K, Bourantas KL. Sfagos C, et al. Among authors: bourantas kl. Mult Scler. 2005 Jun;11(3):272-5. doi: 10.1191/1352458505ms1171oa. Mult Scler. 2005. PMID: 15957506

8

Serum levels of soluble interleukin-2 receptor alpha (sIL-2Ralpha) as a predictor of outcome in brucellosis.

Makis AC, Galanakis E, Hatzimichael EC, Papadopoulou ZL, Siamopoulou A, Bourantas KL. Makis AC, et al. Among authors: bourantas kl. J Infect. 2005 Oct;51(3):206-10. doi: 10.1016/j.jinf.2004.10.013. Epub 2004 Nov 23. J Infect. 2005. PMID: 16230217 Clinical Trial.

9

Von Hippel-Lindau methylation status in patients with multiple myeloma: a potential predictive factor for the development of bone disease.

Hatzimichael E, Dranitsaris G, Dasoula A, Benetatos L, Stebbing J, Crook T, Bourantas KL. Hatzimichael E, et al. Among authors: bourantas kl. Clin Lymphoma Myeloma. 2009 Jun;9(3):239-42. doi: 10.3816/CLM.2009.n.047. Clin Lymphoma Myeloma. 2009. PMID: 19525194

10

The prolyl-hydroxylase EGLN3 and not EGLN1 is inactivated by methylation in plasma cell neoplasia.

Hatzimichael E, Dasoula A, Shah R, Syed N, Papoudou-Bai A, Coley HM, Dranitsaris G, Bourantas KL, Stebbing J, Crook T. Hatzimichael E, et al. Among authors: bourantas kl. Eur J Haematol. 2010 Jan 1;84(1):47-51. doi: 10.1111/j.1600-0609.2009.01344.x. Epub 2009 Sep 8. Eur J Haematol. 2010. PMID: 19737309

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

124 results

Search Page

Filters